
Results
230
Mid-Large Cap Stocks
230 companies
Bristol-Myers Squibb
Market Cap: US$118.7b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$58.13
7D
1.1%
1Y
23.9%
Johnson & Johnson
Market Cap: US$633.2b
Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
JNJ
US$263.04
7D
3.3%
1Y
68.6%
Zoetis
Market Cap: US$31.4b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
ZTS
US$74.80
7D
-1.7%
1Y
-53.0%
Gilead Sciences
Market Cap: US$163.0b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$131.27
7D
2.7%
1Y
17.5%
Amgen
Market Cap: US$201.9b
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
AMGN
US$374.15
7D
4.4%
1Y
25.5%
AbbVie
Market Cap: US$461.3b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$261.07
7D
3.0%
1Y
37.9%
Merck
Market Cap: US$320.0b
Operates as a healthcare company worldwide.
MRK
US$129.56
7D
0.7%
1Y
60.1%
Phibro Animal Health
Market Cap: US$1.3b
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
PAHC
US$33.26
7D
5.0%
1Y
18.8%
Agilent Technologies
Market Cap: US$36.9b
Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
A
US$130.69
7D
-3.9%
1Y
7.7%
Pfizer
Market Cap: US$138.6b
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
PFE
US$24.32
7D
0.1%
1Y
-4.2%
Perrigo
Market Cap: US$1.5b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$11.02
7D
10.8%
1Y
-59.5%
Danaher
Market Cap: US$140.1b
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
DHR
US$197.93
7D
0.9%
1Y
-2.6%
Qiagen
Market Cap: US$8.3b
Provides sample to insight solutions that transform biological samples into molecular insights worldwide.
QGEN
US$40.10
7D
1.8%
1Y
-21.2%
Viatris
Market Cap: US$19.4b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$16.70
7D
2.3%
1Y
79.2%
Royalty Pharma
Market Cap: US$33.3b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$57.77
7D
2.7%
1Y
58.8%
AnaptysBio
Market Cap: US$1.8b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$63.42
7D
0.4%
1Y
167.0%
Hisamitsu Pharmaceutical
Market Cap: US$8.2b
Manufactures and sells pharmaceuticals in Japan.
HTSU.Y
US$4.55
7D
0%
1Y
n/a
UroGen Pharma
Market Cap: US$1.9b
A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$38.02
7D
10.1%
1Y
180.0%
BioNTech
Market Cap: US$24.7b
Engages in the development and commercialization of immunotherapies in Germany.
BNTX
US$97.55
7D
6.9%
1Y
-11.3%
TG Therapeutics
Market Cap: US$7.6b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$53.31
7D
-4.5%
1Y
45.2%
Olema Pharmaceuticals
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
OLMA
US$12.64
7D
11.0%
1Y
176.6%
Trulieve Cannabis
Market Cap: US$1.9b
Operates as a cannabis retailer in the United States.
TRLV
US$9.78
7D
8.8%
1Y
153.4%
ACADIA Pharmaceuticals
Market Cap: US$4.4b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$25.97
7D
2.6%
1Y
24.0%
Organon
Market Cap: US$3.6b
Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$13.55
7D
0.4%
1Y
36.0%
Adaptive Biotechnologies
Market Cap: US$3.4b
A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
ADPT
US$21.19
7D
1.1%
1Y
79.6%
Amylyx Pharmaceuticals
Market Cap: US$2.0b
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
AMLX
US$18.27
7D
2.7%
1Y
190.0%
Trevi Therapeutics
Market Cap: US$2.5b
A clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$17.93
7D
-1.2%
1Y
201.3%
Revolution Medicines
Market Cap: US$40.2b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$189.24
7D
3.9%
1Y
399.7%
Biogen
Market Cap: US$31.9b
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
BIIB
US$216.12
7D
0.04%
1Y
62.7%
ADMA Biologics
Market Cap: US$2.1b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$8.95
7D
2.3%
1Y
-51.0%
AtaiBeckley
Market Cap: US$1.9b
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
ATAI
US$5.19
7D
-1.9%
1Y
87.4%
Exelixis
Market Cap: US$14.0b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$55.85
7D
2.0%
1Y
21.0%
Alnylam Pharmaceuticals
Market Cap: US$41.8b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$312.78
7D
7.3%
1Y
-5.8%
Tempus AI
Market Cap: US$10.8b
Operates as a healthcare technology company in the United States.
TEM
US$60.27
7D
7.4%
1Y
-1.1%
Medpace Holdings
Market Cap: US$15.9b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$557.60
7D
5.8%
1Y
73.4%
BioLife Solutions
Market Cap: US$1.4b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$28.11
7D
-2.0%
1Y
23.1%